Evidence that a synthetic amyloid-ß oligomer-binding peptide (ABP) targets amyloid-ß deposits in transgenic mouse brain and human Alzheimer's disease brain

Download
  1. Get@NRC: Evidence that a synthetic amyloid-ß oligomer-binding peptide (ABP) targets amyloid-ß deposits in transgenic mouse brain and human Alzheimer's disease brain (Opens in a new window)
DOIResolve DOI: http://doi.org/10.1016/j.bbrc.2014.02.064
AuthorSearch for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for:
TypeArticle
Journal titleBiochemical and Biophysical Research Communications
ISSN1090-2104
Volume445
Issue3
Pages656660; # of pages: 5
Subjectamyloid beta protein; amyloid beta protein[1-42]; amyloid beta protein[25-35]; oligomer; synthetic peptide; Alzheimer disease; animal experiment; animal model; animal tissue; apoptosis; article; brain; brain cortex; brain tissue; controlled study; hippocampus; human; human tissue; immunohistology; microinjection; mouse; neuroblast; nonhuman; nucleotide sequence; priority journal; protein aggregation; protein targeting; transgenic mouse; Mus musculus; AD transgenic mice; Alzheimer's disease; Amyloid binding peptide; Aβ(1-42) oligomers; Human AD brains; PCM-1 protein; Aged; Aged, 80 and over; Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Animals; Autoantigens; Brain; Cell Cycle Proteins; Cell Line; Humans; Male; Mice; Mice, Transgenic; Middle Aged; Molecular Sequence Data; Peptide Fragments; Peptides; Protein Binding
AbstractThe synthetic ~5kDa ABP (amyloid-ß binding peptide) consists of a region of the 228kDa human pericentrioloar material-1 (PCM-1) protein that selectively and avidly binds in vitro Aβ1-42 oligomers, believed to be key co-drivers of Alzheimer's disease (AD), but not monomers (Chakravarthy et al., (2013) [3]). ABP also prevents Aß1-42 from triggering the apoptotic death of cultured human SHSY5Y neuroblasts, likely by sequestering Aß oligomers, suggesting that it might be a potential AD therapeutic. Here we support this possibility by showing that ABP also recognizes and binds Aβ1-42 aggregates in sections of cortices and hippocampi from brains of AD transgenic mice and human AD patients. More importantly, ABP targets Aβ1-42 aggregates when microinjected into the hippocampi of the brains of live AD transgenic mice. © 2014.
Publication date
LanguageEnglish
AffiliationNational Research Council Canada (NRC-CNRC); Human Health Therapeutics (HHT-TSH)
Peer reviewedYes
NPARC number21272242
Export citationExport as RIS
Report a correctionReport a correction
Record identifier99784d6c-3fd9-4e99-9772-3d13f62a4021
Record created2014-07-23
Record modified2016-05-09
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)